Drug intelligence / Profile preview

BR2008

Development stage: Phase 1
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR2008 is a small molecule drug candidate initially developed by Boryung Corp. It is being investigated primarily for the treatment of neoplasms (cancers) and digestive system disorders. The mechanism of action for BR2008 has not been disclosed or remains unknown. As of the latest available information, its highest global R&D status is Phase 1 clinical trials[1][4]. The drug is administered orally[4].

Beyond the preview

Go deeper on BR2008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR2008.

Explore the full profile